Members in the News
We are proud of our member’s accomplishments! That’s why when there’s good news to share, we want the world to know. Members in the News features news releases and announcements from CEO Roundtable member companies. Please join us in congratulating these folks.
March 12, 2017 — Katya Tsaioun, PhD, Senior Research Associate at Johns Hopkins Bloomberg School of Public Health is leading a team whose objective is to determine the effectiveness of animal testing at predicting toxicity in humans. The research is to be conducted over the next year using data from 10 approved drugs.
Boston biotech company Acetylon Pharmaceuticals Inc., which is developing drugs to treat blood cancer and other diseases, has announced it has reached an agreement to be acquired by Celgene Corp. Before the takeover is done, Acetylon will spin out some of its non-cancer drug candidates into a separate company called Regenacy Pharmaceuticals Inc.
August 5, 2016 — Mark Engelberg, CEO of TimeLinx Software, was recently recognized nationally by CIO Review as a “Top 20 Project Management Solutions Provider.” CIO Review is a technology magazine in the U.S. that discusses how the enterprise solutions of today can redefine the business goals of tomorrow.
July 14, 2016 NEW YORK (GenomeWeb) — Hong Kong-based venture capital group ORI Healthcare Fund announced that it made an $18 million investment in Boston-based cancer molecular diagnostics startup Pillar Biosciences. Pillar is advancing a patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit.
January 9, 2017 — Kees Been, CEO of Lysosomal Therapeutics (LTI) has announced that Allergan, a leading global pharmaceutical company, has purchased the option to acquire Lysosomal. The purchase will mark Allergan’s entrance into Parkinson’s Disease. LTI is dedicated to innovative small-molecule R & D in the field of neurodegeneration.
Oct. 31, 2016 — Inc. Magazine has ranked ListEngage, Inc. No. 1,224 on its 35th annual Inc. 5000, the most prestigious ranking of the nation’s fastest-growing private companies. ListEngage, an email marketing company outside of Boston, has placed on the list two years in a row, with 2016 representing a big jump from the company’s previous position of 3,356.
July 28, 2016 — Seth Earley, CEO of Earley Information Science — Artificial intelligence is hot, but also daunting. The latest advances [cognitive computing, machine learning, deep learning] … sound complicated and expensive … But the good news is that the early dividends from AI are already within reach of most midsize companies …
June 25, 2016 — PC Zhu, COO of Mass Innovation Labs, was featured in the San Francisco Business Times for his company’s efforts to solve the lab space problems for biotech start-ups. Labs provides 124,000 square feet of built out bio-lab space in Cambridge, MA. Start-up companies can use this space at affordable rates.
S+H Construction founders Alex Slive and Doug Hanna announced today that they have successfully come to an agreement with one of their own to purchase S+H Construction. Sarah Lawson, a project manager who has been with the company for almost 10 years, will purchase the company and carry on S+H’s proud design/build tradition.
Oct. 28, 2016 — Boston Logic has received significant growth investment from Providence Strategic Growth (PSG), the growth equity affiliate of Providence Equity Partners, a leading global private equity firm with $47 billion in assets under management. The funds will be used to provide the firm’s real estate customers with enhanced technologies.
July 28, 2016 — DealerRater CEO Gary Tucker has announced the sale of DealerRater.com, the industry’s largest automotive consumer review website, to Cars.com. On dealerrater.com, buyers decide what vehicle they want, where they want to buy it, and the sales person with whom they wish to do business before going out the door.
June 7, 2016 — Leslie Williams, President & CEO of ImmunsanT and member of the biotech CEO Roundtable, announced good results from two recent trials for Nexvax2, a new therapy for celiac disease. Celiac disease is an immune-medicated gastrointestinal disease caused by dietary gluten. Treatments have proven to be very difficult.
CEO Roundtable is made up of private, peer advisory groups of 8 to 12 members from non-competing companies. These peer groups provide a forum for invigorating exchanges of information, ideas, and insights.
© 2016 - 2018 CEO Roundtable LLC
117 Bridle Path
North Andover, MA 01845-2009